Global PDE 4 Inhibitors Market Growth 2026-2032
The global PDE 4 Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for PDE 4 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for PDE 4 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for PDE 4 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key PDE 4 Inhibitors players cover Pfizer(Anacor), Arcutis Biotherapeutics, UNION Therapeutics, Innovent Biologics, Inc., Amgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “PDE 4 Inhibitors Industry Forecast” looks at past sales and reviews total world PDE 4 Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected PDE 4 Inhibitors sales for 2026 through 2032. With PDE 4 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PDE 4 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global PDE 4 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PDE 4 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PDE 4 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PDE 4 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PDE 4 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of PDE 4 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
United States market for PDE 4 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for PDE 4 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for PDE 4 Inhibitors is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key PDE 4 Inhibitors players cover Pfizer(Anacor), Arcutis Biotherapeutics, UNION Therapeutics, Innovent Biologics, Inc., Amgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “PDE 4 Inhibitors Industry Forecast” looks at past sales and reviews total world PDE 4 Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected PDE 4 Inhibitors sales for 2026 through 2032. With PDE 4 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PDE 4 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global PDE 4 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PDE 4 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PDE 4 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PDE 4 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PDE 4 Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of PDE 4 Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Rolipram
- Tetomilast
- Cilomilast
- Criborole
- Apremilast
- Roflumilast
- Others
- Psoriasis
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Ankylosing Spondylitis (AS)
- Inflammatory Bowel Disease (IBD)
- Atopic Dermatitis
- Rheumatoid Arthritis (RA)
- Systemic Lupus Erythematosus (SLE)
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer(Anacor)
- Arcutis Biotherapeutics
- UNION Therapeutics
- Innovent Biologics, Inc.
- Amgen
- Ralington pharma LLP
- Beijing Biolab Technology Co., Ltd.
- Nycomed
- Forest
- Bristol Myers
- GSK
- What is the 10-year outlook for the global PDE 4 Inhibitors market?
- What factors are driving PDE 4 Inhibitors market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do PDE 4 Inhibitors market opportunities vary by end market size?
- How does PDE 4 Inhibitors break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PDE 4 Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for PDE 4 Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for PDE 4 Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 PDE 4 Inhibitors Segment by Type
2.2.1 Rolipram
2.2.2 Tetomilast
2.2.3 Cilomilast
2.2.4 Criborole
2.2.5 Apremilast
2.2.6 Roflumilast
2.2.7 Others
2.2.8 PDE 4 Inhibitors Sales by Type
2.2.8.1 Global PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
2.2.8.2 Global PDE 4 Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.8.3 Global PDE 4 Inhibitors Sale Price by Type (2021-2026)
2.3 PDE 4 Inhibitors Segment by Application
2.3.1 Psoriasis
2.3.2 Chronic Obstructive Pulmonary Disease (COPD)
2.3.3 Asthma
2.3.4 Ankylosing Spondylitis (AS)
2.3.5 Inflammatory Bowel Disease (IBD)
2.3.6 Atopic Dermatitis
2.3.7 Rheumatoid Arthritis (RA)
2.3.8 Systemic Lupus Erythematosus (SLE)
2.3.9 Others
2.3.10 PDE 4 Inhibitors Sales by Application
2.3.10.1 Global PDE 4 Inhibitors Sale Market Share by Application (2021-2026)
2.3.10.2 Global PDE 4 Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.10.3 Global PDE 4 Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global PDE 4 Inhibitors Breakdown Data by Company
3.1.1 Global PDE 4 Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global PDE 4 Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global PDE 4 Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global PDE 4 Inhibitors Revenue by Company (2021-2026)
3.2.2 Global PDE 4 Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global PDE 4 Inhibitors Sale Price by Company
3.4 Key Manufacturers PDE 4 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PDE 4 Inhibitors Product Location Distribution
3.4.2 Players PDE 4 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PDE 4 INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic PDE 4 Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global PDE 4 Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global PDE 4 Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic PDE 4 Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global PDE 4 Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global PDE 4 Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas PDE 4 Inhibitors Sales Growth
4.4 APAC PDE 4 Inhibitors Sales Growth
4.5 Europe PDE 4 Inhibitors Sales Growth
4.6 Middle East & Africa PDE 4 Inhibitors Sales Growth
5 AMERICAS
5.1 Americas PDE 4 Inhibitors Sales by Country
5.1.1 Americas PDE 4 Inhibitors Sales by Country (2021-2026)
5.1.2 Americas PDE 4 Inhibitors Revenue by Country (2021-2026)
5.2 Americas PDE 4 Inhibitors Sales by Type (2021-2026)
5.3 Americas PDE 4 Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PDE 4 Inhibitors Sales by Region
6.1.1 APAC PDE 4 Inhibitors Sales by Region (2021-2026)
6.1.2 APAC PDE 4 Inhibitors Revenue by Region (2021-2026)
6.2 APAC PDE 4 Inhibitors Sales by Type (2021-2026)
6.3 APAC PDE 4 Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PDE 4 Inhibitors by Country
7.1.1 Europe PDE 4 Inhibitors Sales by Country (2021-2026)
7.1.2 Europe PDE 4 Inhibitors Revenue by Country (2021-2026)
7.2 Europe PDE 4 Inhibitors Sales by Type (2021-2026)
7.3 Europe PDE 4 Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PDE 4 Inhibitors by Country
8.1.1 Middle East & Africa PDE 4 Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa PDE 4 Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa PDE 4 Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa PDE 4 Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PDE 4 Inhibitors
10.3 Manufacturing Process Analysis of PDE 4 Inhibitors
10.4 Industry Chain Structure of PDE 4 Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PDE 4 Inhibitors Distributors
11.3 PDE 4 Inhibitors Customer
12 WORLD FORECAST REVIEW FOR PDE 4 INHIBITORS BY GEOGRAPHIC REGION
12.1 Global PDE 4 Inhibitors Market Size Forecast by Region
12.1.1 Global PDE 4 Inhibitors Forecast by Region (2027-2032)
12.1.2 Global PDE 4 Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global PDE 4 Inhibitors Forecast by Type (2027-2032)
12.7 Global PDE 4 Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer(Anacor)
13.1.1 Pfizer(Anacor) Company Information
13.1.2 Pfizer(Anacor) PDE 4 Inhibitors Product Portfolios and Specifications
13.1.3 Pfizer(Anacor) PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer(Anacor) Main Business Overview
13.1.5 Pfizer(Anacor) Latest Developments
13.2 Arcutis Biotherapeutics
13.2.1 Arcutis Biotherapeutics Company Information
13.2.2 Arcutis Biotherapeutics PDE 4 Inhibitors Product Portfolios and Specifications
13.2.3 Arcutis Biotherapeutics PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Arcutis Biotherapeutics Main Business Overview
13.2.5 Arcutis Biotherapeutics Latest Developments
13.3 UNION Therapeutics
13.3.1 UNION Therapeutics Company Information
13.3.2 UNION Therapeutics PDE 4 Inhibitors Product Portfolios and Specifications
13.3.3 UNION Therapeutics PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 UNION Therapeutics Main Business Overview
13.3.5 UNION Therapeutics Latest Developments
13.4 Innovent Biologics, Inc.
13.4.1 Innovent Biologics, Inc. Company Information
13.4.2 Innovent Biologics, Inc. PDE 4 Inhibitors Product Portfolios and Specifications
13.4.3 Innovent Biologics, Inc. PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Innovent Biologics, Inc. Main Business Overview
13.4.5 Innovent Biologics, Inc. Latest Developments
13.5 Amgen
13.5.1 Amgen Company Information
13.5.2 Amgen PDE 4 Inhibitors Product Portfolios and Specifications
13.5.3 Amgen PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Amgen Main Business Overview
13.5.5 Amgen Latest Developments
13.6 Ralington pharma LLP
13.6.1 Ralington pharma LLP Company Information
13.6.2 Ralington pharma LLP PDE 4 Inhibitors Product Portfolios and Specifications
13.6.3 Ralington pharma LLP PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Ralington pharma LLP Main Business Overview
13.6.5 Ralington pharma LLP Latest Developments
13.7 Beijing Biolab Technology Co., Ltd.
13.7.1 Beijing Biolab Technology Co., Ltd. Company Information
13.7.2 Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Product Portfolios and Specifications
13.7.3 Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Beijing Biolab Technology Co., Ltd. Main Business Overview
13.7.5 Beijing Biolab Technology Co., Ltd. Latest Developments
13.8 Nycomed
13.8.1 Nycomed Company Information
13.8.2 Nycomed PDE 4 Inhibitors Product Portfolios and Specifications
13.8.3 Nycomed PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nycomed Main Business Overview
13.8.5 Nycomed Latest Developments
13.9 Forest
13.9.1 Forest Company Information
13.9.2 Forest PDE 4 Inhibitors Product Portfolios and Specifications
13.9.3 Forest PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Forest Main Business Overview
13.9.5 Forest Latest Developments
13.10 Bristol Myers
13.10.1 Bristol Myers Company Information
13.10.2 Bristol Myers PDE 4 Inhibitors Product Portfolios and Specifications
13.10.3 Bristol Myers PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Bristol Myers Main Business Overview
13.10.5 Bristol Myers Latest Developments
13.11 GSK
13.11.1 GSK Company Information
13.11.2 GSK PDE 4 Inhibitors Product Portfolios and Specifications
13.11.3 GSK PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 GSK Main Business Overview
13.11.5 GSK Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PDE 4 Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for PDE 4 Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for PDE 4 Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 PDE 4 Inhibitors Segment by Type
2.2.1 Rolipram
2.2.2 Tetomilast
2.2.3 Cilomilast
2.2.4 Criborole
2.2.5 Apremilast
2.2.6 Roflumilast
2.2.7 Others
2.2.8 PDE 4 Inhibitors Sales by Type
2.2.8.1 Global PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
2.2.8.2 Global PDE 4 Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.8.3 Global PDE 4 Inhibitors Sale Price by Type (2021-2026)
2.3 PDE 4 Inhibitors Segment by Application
2.3.1 Psoriasis
2.3.2 Chronic Obstructive Pulmonary Disease (COPD)
2.3.3 Asthma
2.3.4 Ankylosing Spondylitis (AS)
2.3.5 Inflammatory Bowel Disease (IBD)
2.3.6 Atopic Dermatitis
2.3.7 Rheumatoid Arthritis (RA)
2.3.8 Systemic Lupus Erythematosus (SLE)
2.3.9 Others
2.3.10 PDE 4 Inhibitors Sales by Application
2.3.10.1 Global PDE 4 Inhibitors Sale Market Share by Application (2021-2026)
2.3.10.2 Global PDE 4 Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.10.3 Global PDE 4 Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global PDE 4 Inhibitors Breakdown Data by Company
3.1.1 Global PDE 4 Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global PDE 4 Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global PDE 4 Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global PDE 4 Inhibitors Revenue by Company (2021-2026)
3.2.2 Global PDE 4 Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global PDE 4 Inhibitors Sale Price by Company
3.4 Key Manufacturers PDE 4 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PDE 4 Inhibitors Product Location Distribution
3.4.2 Players PDE 4 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PDE 4 INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic PDE 4 Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global PDE 4 Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global PDE 4 Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic PDE 4 Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global PDE 4 Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global PDE 4 Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas PDE 4 Inhibitors Sales Growth
4.4 APAC PDE 4 Inhibitors Sales Growth
4.5 Europe PDE 4 Inhibitors Sales Growth
4.6 Middle East & Africa PDE 4 Inhibitors Sales Growth
5 AMERICAS
5.1 Americas PDE 4 Inhibitors Sales by Country
5.1.1 Americas PDE 4 Inhibitors Sales by Country (2021-2026)
5.1.2 Americas PDE 4 Inhibitors Revenue by Country (2021-2026)
5.2 Americas PDE 4 Inhibitors Sales by Type (2021-2026)
5.3 Americas PDE 4 Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PDE 4 Inhibitors Sales by Region
6.1.1 APAC PDE 4 Inhibitors Sales by Region (2021-2026)
6.1.2 APAC PDE 4 Inhibitors Revenue by Region (2021-2026)
6.2 APAC PDE 4 Inhibitors Sales by Type (2021-2026)
6.3 APAC PDE 4 Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PDE 4 Inhibitors by Country
7.1.1 Europe PDE 4 Inhibitors Sales by Country (2021-2026)
7.1.2 Europe PDE 4 Inhibitors Revenue by Country (2021-2026)
7.2 Europe PDE 4 Inhibitors Sales by Type (2021-2026)
7.3 Europe PDE 4 Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PDE 4 Inhibitors by Country
8.1.1 Middle East & Africa PDE 4 Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa PDE 4 Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa PDE 4 Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa PDE 4 Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PDE 4 Inhibitors
10.3 Manufacturing Process Analysis of PDE 4 Inhibitors
10.4 Industry Chain Structure of PDE 4 Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PDE 4 Inhibitors Distributors
11.3 PDE 4 Inhibitors Customer
12 WORLD FORECAST REVIEW FOR PDE 4 INHIBITORS BY GEOGRAPHIC REGION
12.1 Global PDE 4 Inhibitors Market Size Forecast by Region
12.1.1 Global PDE 4 Inhibitors Forecast by Region (2027-2032)
12.1.2 Global PDE 4 Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global PDE 4 Inhibitors Forecast by Type (2027-2032)
12.7 Global PDE 4 Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer(Anacor)
13.1.1 Pfizer(Anacor) Company Information
13.1.2 Pfizer(Anacor) PDE 4 Inhibitors Product Portfolios and Specifications
13.1.3 Pfizer(Anacor) PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer(Anacor) Main Business Overview
13.1.5 Pfizer(Anacor) Latest Developments
13.2 Arcutis Biotherapeutics
13.2.1 Arcutis Biotherapeutics Company Information
13.2.2 Arcutis Biotherapeutics PDE 4 Inhibitors Product Portfolios and Specifications
13.2.3 Arcutis Biotherapeutics PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Arcutis Biotherapeutics Main Business Overview
13.2.5 Arcutis Biotherapeutics Latest Developments
13.3 UNION Therapeutics
13.3.1 UNION Therapeutics Company Information
13.3.2 UNION Therapeutics PDE 4 Inhibitors Product Portfolios and Specifications
13.3.3 UNION Therapeutics PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 UNION Therapeutics Main Business Overview
13.3.5 UNION Therapeutics Latest Developments
13.4 Innovent Biologics, Inc.
13.4.1 Innovent Biologics, Inc. Company Information
13.4.2 Innovent Biologics, Inc. PDE 4 Inhibitors Product Portfolios and Specifications
13.4.3 Innovent Biologics, Inc. PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Innovent Biologics, Inc. Main Business Overview
13.4.5 Innovent Biologics, Inc. Latest Developments
13.5 Amgen
13.5.1 Amgen Company Information
13.5.2 Amgen PDE 4 Inhibitors Product Portfolios and Specifications
13.5.3 Amgen PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Amgen Main Business Overview
13.5.5 Amgen Latest Developments
13.6 Ralington pharma LLP
13.6.1 Ralington pharma LLP Company Information
13.6.2 Ralington pharma LLP PDE 4 Inhibitors Product Portfolios and Specifications
13.6.3 Ralington pharma LLP PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Ralington pharma LLP Main Business Overview
13.6.5 Ralington pharma LLP Latest Developments
13.7 Beijing Biolab Technology Co., Ltd.
13.7.1 Beijing Biolab Technology Co., Ltd. Company Information
13.7.2 Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Product Portfolios and Specifications
13.7.3 Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Beijing Biolab Technology Co., Ltd. Main Business Overview
13.7.5 Beijing Biolab Technology Co., Ltd. Latest Developments
13.8 Nycomed
13.8.1 Nycomed Company Information
13.8.2 Nycomed PDE 4 Inhibitors Product Portfolios and Specifications
13.8.3 Nycomed PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nycomed Main Business Overview
13.8.5 Nycomed Latest Developments
13.9 Forest
13.9.1 Forest Company Information
13.9.2 Forest PDE 4 Inhibitors Product Portfolios and Specifications
13.9.3 Forest PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Forest Main Business Overview
13.9.5 Forest Latest Developments
13.10 Bristol Myers
13.10.1 Bristol Myers Company Information
13.10.2 Bristol Myers PDE 4 Inhibitors Product Portfolios and Specifications
13.10.3 Bristol Myers PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Bristol Myers Main Business Overview
13.10.5 Bristol Myers Latest Developments
13.11 GSK
13.11.1 GSK Company Information
13.11.2 GSK PDE 4 Inhibitors Product Portfolios and Specifications
13.11.3 GSK PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 GSK Main Business Overview
13.11.5 GSK Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. PDE 4 Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. PDE 4 Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Rolipram
Table 4. Major Players of Tetomilast
Table 5. Major Players of Cilomilast
Table 6. Major Players of Criborole
Table 7. Major Players of Apremilast
Table 8. Major Players of Roflumilast
Table 9. Major Players of Others
Table 10. Global PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 11. Global PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Table 12. Global PDE 4 Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 13. Global PDE 4 Inhibitors Revenue Market Share by Type (2021-2026)
Table 14. Global PDE 4 Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 15. Global PDE 4 Inhibitors Sale by Application (2021-2026) & (K Units)
Table 16. Global PDE 4 Inhibitors Sale Market Share by Application (2021-2026)
Table 17. Global PDE 4 Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 18. Global PDE 4 Inhibitors Revenue Market Share by Application (2021-2026)
Table 19. Global PDE 4 Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 20. Global PDE 4 Inhibitors Sales by Company (2021-2026) & (K Units)
Table 21. Global PDE 4 Inhibitors Sales Market Share by Company (2021-2026)
Table 22. Global PDE 4 Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 23. Global PDE 4 Inhibitors Revenue Market Share by Company (2021-2026)
Table 24. Global PDE 4 Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 25. Key Manufacturers PDE 4 Inhibitors Producing Area Distribution and Sales Area
Table 26. Players PDE 4 Inhibitors Products Offered
Table 27. PDE 4 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global PDE 4 Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 31. Global PDE 4 Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 32. Global PDE 4 Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 33. Global PDE 4 Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 34. Global PDE 4 Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 35. Global PDE 4 Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 36. Global PDE 4 Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 37. Global PDE 4 Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 38. Americas PDE 4 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 39. Americas PDE 4 Inhibitors Sales Market Share by Country (2021-2026)
Table 40. Americas PDE 4 Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 41. Americas PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 42. Americas PDE 4 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 43. APAC PDE 4 Inhibitors Sales by Region (2021-2026) & (K Units)
Table 44. APAC PDE 4 Inhibitors Sales Market Share by Region (2021-2026)
Table 45. APAC PDE 4 Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 46. APAC PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 47. APAC PDE 4 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 48. Europe PDE 4 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 49. Europe PDE 4 Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 50. Europe PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 51. Europe PDE 4 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 52. Middle East & Africa PDE 4 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 53. Middle East & Africa PDE 4 Inhibitors Revenue Market Share by Country (2021-2026)
Table 54. Middle East & Africa PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 55. Middle East & Africa PDE 4 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of PDE 4 Inhibitors
Table 57. Key Market Challenges & Risks of PDE 4 Inhibitors
Table 58. Key Industry Trends of PDE 4 Inhibitors
Table 59. PDE 4 Inhibitors Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. PDE 4 Inhibitors Distributors List
Table 62. PDE 4 Inhibitors Customer List
Table 63. Global PDE 4 Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 64. Global PDE 4 Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Americas PDE 4 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Americas PDE 4 Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. APAC PDE 4 Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 68. APAC PDE 4 Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 69. Europe PDE 4 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Europe PDE 4 Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Middle East & Africa PDE 4 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 72. Middle East & Africa PDE 4 Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Global PDE 4 Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 74. Global PDE 4 Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 75. Global PDE 4 Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 76. Global PDE 4 Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 77. Pfizer(Anacor) Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer(Anacor) PDE 4 Inhibitors Product Portfolios and Specifications
Table 79. Pfizer(Anacor) PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Pfizer(Anacor) Main Business
Table 81. Pfizer(Anacor) Latest Developments
Table 82. Arcutis Biotherapeutics Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 83. Arcutis Biotherapeutics PDE 4 Inhibitors Product Portfolios and Specifications
Table 84. Arcutis Biotherapeutics PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Arcutis Biotherapeutics Main Business
Table 86. Arcutis Biotherapeutics Latest Developments
Table 87. UNION Therapeutics Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 88. UNION Therapeutics PDE 4 Inhibitors Product Portfolios and Specifications
Table 89. UNION Therapeutics PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. UNION Therapeutics Main Business
Table 91. UNION Therapeutics Latest Developments
Table 92. Innovent Biologics, Inc. Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 93. Innovent Biologics, Inc. PDE 4 Inhibitors Product Portfolios and Specifications
Table 94. Innovent Biologics, Inc. PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Innovent Biologics, Inc. Main Business
Table 96. Innovent Biologics, Inc. Latest Developments
Table 97. Amgen Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 98. Amgen PDE 4 Inhibitors Product Portfolios and Specifications
Table 99. Amgen PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Amgen Main Business
Table 101. Amgen Latest Developments
Table 102. Ralington pharma LLP Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 103. Ralington pharma LLP PDE 4 Inhibitors Product Portfolios and Specifications
Table 104. Ralington pharma LLP PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Ralington pharma LLP Main Business
Table 106. Ralington pharma LLP Latest Developments
Table 107. Beijing Biolab Technology Co., Ltd. Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 108. Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Product Portfolios and Specifications
Table 109. Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Beijing Biolab Technology Co., Ltd. Main Business
Table 111. Beijing Biolab Technology Co., Ltd. Latest Developments
Table 112. Nycomed Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 113. Nycomed PDE 4 Inhibitors Product Portfolios and Specifications
Table 114. Nycomed PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Nycomed Main Business
Table 116. Nycomed Latest Developments
Table 117. Forest Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 118. Forest PDE 4 Inhibitors Product Portfolios and Specifications
Table 119. Forest PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Forest Main Business
Table 121. Forest Latest Developments
Table 122. Bristol Myers Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 123. Bristol Myers PDE 4 Inhibitors Product Portfolios and Specifications
Table 124. Bristol Myers PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Bristol Myers Main Business
Table 126. Bristol Myers Latest Developments
Table 127. GSK Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 128. GSK PDE 4 Inhibitors Product Portfolios and Specifications
Table 129. GSK PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. GSK Main Business
Table 131. GSK Latest Developments
Table 1. PDE 4 Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. PDE 4 Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Rolipram
Table 4. Major Players of Tetomilast
Table 5. Major Players of Cilomilast
Table 6. Major Players of Criborole
Table 7. Major Players of Apremilast
Table 8. Major Players of Roflumilast
Table 9. Major Players of Others
Table 10. Global PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 11. Global PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Table 12. Global PDE 4 Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 13. Global PDE 4 Inhibitors Revenue Market Share by Type (2021-2026)
Table 14. Global PDE 4 Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 15. Global PDE 4 Inhibitors Sale by Application (2021-2026) & (K Units)
Table 16. Global PDE 4 Inhibitors Sale Market Share by Application (2021-2026)
Table 17. Global PDE 4 Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 18. Global PDE 4 Inhibitors Revenue Market Share by Application (2021-2026)
Table 19. Global PDE 4 Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 20. Global PDE 4 Inhibitors Sales by Company (2021-2026) & (K Units)
Table 21. Global PDE 4 Inhibitors Sales Market Share by Company (2021-2026)
Table 22. Global PDE 4 Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 23. Global PDE 4 Inhibitors Revenue Market Share by Company (2021-2026)
Table 24. Global PDE 4 Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 25. Key Manufacturers PDE 4 Inhibitors Producing Area Distribution and Sales Area
Table 26. Players PDE 4 Inhibitors Products Offered
Table 27. PDE 4 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global PDE 4 Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 31. Global PDE 4 Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 32. Global PDE 4 Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 33. Global PDE 4 Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 34. Global PDE 4 Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 35. Global PDE 4 Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 36. Global PDE 4 Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 37. Global PDE 4 Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 38. Americas PDE 4 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 39. Americas PDE 4 Inhibitors Sales Market Share by Country (2021-2026)
Table 40. Americas PDE 4 Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 41. Americas PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 42. Americas PDE 4 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 43. APAC PDE 4 Inhibitors Sales by Region (2021-2026) & (K Units)
Table 44. APAC PDE 4 Inhibitors Sales Market Share by Region (2021-2026)
Table 45. APAC PDE 4 Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 46. APAC PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 47. APAC PDE 4 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 48. Europe PDE 4 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 49. Europe PDE 4 Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 50. Europe PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 51. Europe PDE 4 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 52. Middle East & Africa PDE 4 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 53. Middle East & Africa PDE 4 Inhibitors Revenue Market Share by Country (2021-2026)
Table 54. Middle East & Africa PDE 4 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 55. Middle East & Africa PDE 4 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of PDE 4 Inhibitors
Table 57. Key Market Challenges & Risks of PDE 4 Inhibitors
Table 58. Key Industry Trends of PDE 4 Inhibitors
Table 59. PDE 4 Inhibitors Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. PDE 4 Inhibitors Distributors List
Table 62. PDE 4 Inhibitors Customer List
Table 63. Global PDE 4 Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 64. Global PDE 4 Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Americas PDE 4 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Americas PDE 4 Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. APAC PDE 4 Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 68. APAC PDE 4 Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 69. Europe PDE 4 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Europe PDE 4 Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Middle East & Africa PDE 4 Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 72. Middle East & Africa PDE 4 Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Global PDE 4 Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 74. Global PDE 4 Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 75. Global PDE 4 Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 76. Global PDE 4 Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 77. Pfizer(Anacor) Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer(Anacor) PDE 4 Inhibitors Product Portfolios and Specifications
Table 79. Pfizer(Anacor) PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Pfizer(Anacor) Main Business
Table 81. Pfizer(Anacor) Latest Developments
Table 82. Arcutis Biotherapeutics Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 83. Arcutis Biotherapeutics PDE 4 Inhibitors Product Portfolios and Specifications
Table 84. Arcutis Biotherapeutics PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Arcutis Biotherapeutics Main Business
Table 86. Arcutis Biotherapeutics Latest Developments
Table 87. UNION Therapeutics Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 88. UNION Therapeutics PDE 4 Inhibitors Product Portfolios and Specifications
Table 89. UNION Therapeutics PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. UNION Therapeutics Main Business
Table 91. UNION Therapeutics Latest Developments
Table 92. Innovent Biologics, Inc. Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 93. Innovent Biologics, Inc. PDE 4 Inhibitors Product Portfolios and Specifications
Table 94. Innovent Biologics, Inc. PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Innovent Biologics, Inc. Main Business
Table 96. Innovent Biologics, Inc. Latest Developments
Table 97. Amgen Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 98. Amgen PDE 4 Inhibitors Product Portfolios and Specifications
Table 99. Amgen PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Amgen Main Business
Table 101. Amgen Latest Developments
Table 102. Ralington pharma LLP Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 103. Ralington pharma LLP PDE 4 Inhibitors Product Portfolios and Specifications
Table 104. Ralington pharma LLP PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Ralington pharma LLP Main Business
Table 106. Ralington pharma LLP Latest Developments
Table 107. Beijing Biolab Technology Co., Ltd. Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 108. Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Product Portfolios and Specifications
Table 109. Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Beijing Biolab Technology Co., Ltd. Main Business
Table 111. Beijing Biolab Technology Co., Ltd. Latest Developments
Table 112. Nycomed Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 113. Nycomed PDE 4 Inhibitors Product Portfolios and Specifications
Table 114. Nycomed PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Nycomed Main Business
Table 116. Nycomed Latest Developments
Table 117. Forest Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 118. Forest PDE 4 Inhibitors Product Portfolios and Specifications
Table 119. Forest PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Forest Main Business
Table 121. Forest Latest Developments
Table 122. Bristol Myers Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 123. Bristol Myers PDE 4 Inhibitors Product Portfolios and Specifications
Table 124. Bristol Myers PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Bristol Myers Main Business
Table 126. Bristol Myers Latest Developments
Table 127. GSK Basic Information, PDE 4 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 128. GSK PDE 4 Inhibitors Product Portfolios and Specifications
Table 129. GSK PDE 4 Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. GSK Main Business
Table 131. GSK Latest Developments
LIST OF FIGURES
Figure 1. Picture of PDE 4 Inhibitors
Figure 2. PDE 4 Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PDE 4 Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global PDE 4 Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. PDE 4 Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. PDE 4 Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. PDE 4 Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Rolipram
Figure 12. Product Picture of Tetomilast
Figure 13. Product Picture of Cilomilast
Figure 14. Product Picture of Criborole
Figure 15. Product Picture of Apremilast
Figure 16. Product Picture of Roflumilast
Figure 17. Product Picture of Others
Figure 18. Global PDE 4 Inhibitors Sales Market Share by Type in 2026
Figure 19. Global PDE 4 Inhibitors Revenue Market Share by Type (2021-2026)
Figure 20. PDE 4 Inhibitors Consumed in Psoriasis
Figure 21. Global PDE 4 Inhibitors Market: Psoriasis (2021-2026) & (K Units)
Figure 22. PDE 4 Inhibitors Consumed in Chronic Obstructive Pulmonary Disease (COPD)
Figure 23. Global PDE 4 Inhibitors Market: Chronic Obstructive Pulmonary Disease (COPD) (2021-2026) & (K Units)
Figure 24. PDE 4 Inhibitors Consumed in Asthma
Figure 25. Global PDE 4 Inhibitors Market: Asthma (2021-2026) & (K Units)
Figure 26. PDE 4 Inhibitors Consumed in Ankylosing Spondylitis (AS)
Figure 27. Global PDE 4 Inhibitors Market: Ankylosing Spondylitis (AS) (2021-2026) & (K Units)
Figure 28. PDE 4 Inhibitors Consumed in Inflammatory Bowel Disease (IBD)
Figure 29. Global PDE 4 Inhibitors Market: Inflammatory Bowel Disease (IBD) (2021-2026) & (K Units)
Figure 30. PDE 4 Inhibitors Consumed in Atopic Dermatitis
Figure 31. Global PDE 4 Inhibitors Market: Atopic Dermatitis (2021-2026) & (K Units)
Figure 32. PDE 4 Inhibitors Consumed in Rheumatoid Arthritis (RA)
Figure 33. Global PDE 4 Inhibitors Market: Rheumatoid Arthritis (RA) (2021-2026) & (K Units)
Figure 34. PDE 4 Inhibitors Consumed in Systemic Lupus Erythematosus (SLE)
Figure 35. Global PDE 4 Inhibitors Market: Systemic Lupus Erythematosus (SLE) (2021-2026) & (K Units)
Figure 36. PDE 4 Inhibitors Consumed in Others
Figure 37. Global PDE 4 Inhibitors Market: Others (2021-2026) & (K Units)
Figure 38. Global PDE 4 Inhibitors Sale Market Share by Application (2025)
Figure 39. Global PDE 4 Inhibitors Revenue Market Share by Application in 2026
Figure 40. PDE 4 Inhibitors Sales by Company in 2026 (K Units)
Figure 41. Global PDE 4 Inhibitors Sales Market Share by Company in 2026
Figure 42. PDE 4 Inhibitors Revenue by Company in 2026 ($ millions)
Figure 43. Global PDE 4 Inhibitors Revenue Market Share by Company in 2026
Figure 44. Global PDE 4 Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global PDE 4 Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 46. Americas PDE 4 Inhibitors Sales 2021-2026 (K Units)
Figure 47. Americas PDE 4 Inhibitors Revenue 2021-2026 ($ millions)
Figure 48. APAC PDE 4 Inhibitors Sales 2021-2026 (K Units)
Figure 49. APAC PDE 4 Inhibitors Revenue 2021-2026 ($ millions)
Figure 50. Europe PDE 4 Inhibitors Sales 2021-2026 (K Units)
Figure 51. Europe PDE 4 Inhibitors Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa PDE 4 Inhibitors Sales 2021-2026 (K Units)
Figure 53. Middle East & Africa PDE 4 Inhibitors Revenue 2021-2026 ($ millions)
Figure 54. Americas PDE 4 Inhibitors Sales Market Share by Country in 2026
Figure 55. Americas PDE 4 Inhibitors Revenue Market Share by Country (2021-2026)
Figure 56. Americas PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Figure 57. Americas PDE 4 Inhibitors Sales Market Share by Application (2021-2026)
Figure 58. United States PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC PDE 4 Inhibitors Sales Market Share by Region in 2026
Figure 63. APAC PDE 4 Inhibitors Revenue Market Share by Region (2021-2026)
Figure 64. APAC PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Figure 65. APAC PDE 4 Inhibitors Sales Market Share by Application (2021-2026)
Figure 66. China PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 70. India PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe PDE 4 Inhibitors Sales Market Share by Country in 2026
Figure 74. Europe PDE 4 Inhibitors Revenue Market Share by Country (2021-2026)
Figure 75. Europe PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Figure 76. Europe PDE 4 Inhibitors Sales Market Share by Application (2021-2026)
Figure 77. Germany PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 78. France PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 79. UK PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa PDE 4 Inhibitors Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa PDE 4 Inhibitors Sales Market Share by Application (2021-2026)
Figure 85. Egypt PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of PDE 4 Inhibitors in 2026
Figure 91. Manufacturing Process Analysis of PDE 4 Inhibitors
Figure 92. Industry Chain Structure of PDE 4 Inhibitors
Figure 93. Channels of Distribution
Figure 94. Global PDE 4 Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 95. Global PDE 4 Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global PDE 4 Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global PDE 4 Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global PDE 4 Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global PDE 4 Inhibitors Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of PDE 4 Inhibitors
Figure 2. PDE 4 Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PDE 4 Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global PDE 4 Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. PDE 4 Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. PDE 4 Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. PDE 4 Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Rolipram
Figure 12. Product Picture of Tetomilast
Figure 13. Product Picture of Cilomilast
Figure 14. Product Picture of Criborole
Figure 15. Product Picture of Apremilast
Figure 16. Product Picture of Roflumilast
Figure 17. Product Picture of Others
Figure 18. Global PDE 4 Inhibitors Sales Market Share by Type in 2026
Figure 19. Global PDE 4 Inhibitors Revenue Market Share by Type (2021-2026)
Figure 20. PDE 4 Inhibitors Consumed in Psoriasis
Figure 21. Global PDE 4 Inhibitors Market: Psoriasis (2021-2026) & (K Units)
Figure 22. PDE 4 Inhibitors Consumed in Chronic Obstructive Pulmonary Disease (COPD)
Figure 23. Global PDE 4 Inhibitors Market: Chronic Obstructive Pulmonary Disease (COPD) (2021-2026) & (K Units)
Figure 24. PDE 4 Inhibitors Consumed in Asthma
Figure 25. Global PDE 4 Inhibitors Market: Asthma (2021-2026) & (K Units)
Figure 26. PDE 4 Inhibitors Consumed in Ankylosing Spondylitis (AS)
Figure 27. Global PDE 4 Inhibitors Market: Ankylosing Spondylitis (AS) (2021-2026) & (K Units)
Figure 28. PDE 4 Inhibitors Consumed in Inflammatory Bowel Disease (IBD)
Figure 29. Global PDE 4 Inhibitors Market: Inflammatory Bowel Disease (IBD) (2021-2026) & (K Units)
Figure 30. PDE 4 Inhibitors Consumed in Atopic Dermatitis
Figure 31. Global PDE 4 Inhibitors Market: Atopic Dermatitis (2021-2026) & (K Units)
Figure 32. PDE 4 Inhibitors Consumed in Rheumatoid Arthritis (RA)
Figure 33. Global PDE 4 Inhibitors Market: Rheumatoid Arthritis (RA) (2021-2026) & (K Units)
Figure 34. PDE 4 Inhibitors Consumed in Systemic Lupus Erythematosus (SLE)
Figure 35. Global PDE 4 Inhibitors Market: Systemic Lupus Erythematosus (SLE) (2021-2026) & (K Units)
Figure 36. PDE 4 Inhibitors Consumed in Others
Figure 37. Global PDE 4 Inhibitors Market: Others (2021-2026) & (K Units)
Figure 38. Global PDE 4 Inhibitors Sale Market Share by Application (2025)
Figure 39. Global PDE 4 Inhibitors Revenue Market Share by Application in 2026
Figure 40. PDE 4 Inhibitors Sales by Company in 2026 (K Units)
Figure 41. Global PDE 4 Inhibitors Sales Market Share by Company in 2026
Figure 42. PDE 4 Inhibitors Revenue by Company in 2026 ($ millions)
Figure 43. Global PDE 4 Inhibitors Revenue Market Share by Company in 2026
Figure 44. Global PDE 4 Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global PDE 4 Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 46. Americas PDE 4 Inhibitors Sales 2021-2026 (K Units)
Figure 47. Americas PDE 4 Inhibitors Revenue 2021-2026 ($ millions)
Figure 48. APAC PDE 4 Inhibitors Sales 2021-2026 (K Units)
Figure 49. APAC PDE 4 Inhibitors Revenue 2021-2026 ($ millions)
Figure 50. Europe PDE 4 Inhibitors Sales 2021-2026 (K Units)
Figure 51. Europe PDE 4 Inhibitors Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa PDE 4 Inhibitors Sales 2021-2026 (K Units)
Figure 53. Middle East & Africa PDE 4 Inhibitors Revenue 2021-2026 ($ millions)
Figure 54. Americas PDE 4 Inhibitors Sales Market Share by Country in 2026
Figure 55. Americas PDE 4 Inhibitors Revenue Market Share by Country (2021-2026)
Figure 56. Americas PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Figure 57. Americas PDE 4 Inhibitors Sales Market Share by Application (2021-2026)
Figure 58. United States PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC PDE 4 Inhibitors Sales Market Share by Region in 2026
Figure 63. APAC PDE 4 Inhibitors Revenue Market Share by Region (2021-2026)
Figure 64. APAC PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Figure 65. APAC PDE 4 Inhibitors Sales Market Share by Application (2021-2026)
Figure 66. China PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 70. India PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe PDE 4 Inhibitors Sales Market Share by Country in 2026
Figure 74. Europe PDE 4 Inhibitors Revenue Market Share by Country (2021-2026)
Figure 75. Europe PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Figure 76. Europe PDE 4 Inhibitors Sales Market Share by Application (2021-2026)
Figure 77. Germany PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 78. France PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 79. UK PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa PDE 4 Inhibitors Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa PDE 4 Inhibitors Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa PDE 4 Inhibitors Sales Market Share by Application (2021-2026)
Figure 85. Egypt PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries PDE 4 Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of PDE 4 Inhibitors in 2026
Figure 91. Manufacturing Process Analysis of PDE 4 Inhibitors
Figure 92. Industry Chain Structure of PDE 4 Inhibitors
Figure 93. Channels of Distribution
Figure 94. Global PDE 4 Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 95. Global PDE 4 Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global PDE 4 Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global PDE 4 Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global PDE 4 Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global PDE 4 Inhibitors Revenue Market Share Forecast by Application (2027-2032)
